Gary D Luker Selected Research

Neoplasms (Cancer)

2/2022	Structural effects of morpholine replacement in ZSTK474 on Class I PI3K isoform inhibition: Development of novel MEK/PI3K bifunctional inhibitors.
1/2022	The CXCL12/CXCR4/ACKR3 Signaling Axis Regulates PKM2 and Glycolysis.
1/2022	Iodinated Contrast Material Shortage: Perspectives from the Cancer Imaging Community.
1/2022	Ultrasound-Induced Mechanical Compaction in Acoustically Responsive Scaffolds Promotes Spatiotemporally Modulated Signaling in Triple Negative Breast Cancer.
1/2022	Effects of iron modulation on mesenchymal stem cell-induced drug resistance in estrogen receptor-positive breast cancer.
1/2022	Therapeutic Targeting of Stromal-Tumor HGF-MET Signaling in an Organotypic Triple-Negative Breast Tumor Model.
2/2021	Pre-existing Cell States Control Heterogeneity of Both EGFR and CXCR4 Signaling.
1/2021	Heterogeneous microenvironmental stiffness regulates pro-metastatic functions of breast cancer cells.
1/2021	At the Bench: Pre-clinical evidence for multiple functions of CXCR4 in cancer.
1/2021	The Person in the Images: A Patient Perspective on Cancer Diagnosis, Therapy, and Living with Cancer.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Gary D Luker Research Topics

Disease

73	Neoplasms (Cancer) 02/2022 - 05/2002
28	Breast Neoplasms (Breast Cancer) 01/2022 - 12/2004
25	Neoplasm Metastasis (Metastasis) 01/2020 - 12/2004
9	Triple Negative Breast Neoplasms 01/2022 - 07/2015
8	Infections 09/2008 - 12/2002
4	Virus Diseases (Viral Diseases) 04/2010 - 12/2002
3	Carcinogenesis 02/2022 - 01/2016
3	Disease Progression 01/2022 - 01/2003
3	Glioblastoma (Glioblastoma Multiforme) 12/2021 - 01/2015
3	Colorectal Neoplasms (Colorectal Cancer) 12/2020 - 11/2017
3	Melanoma (Melanoma, Malignant) 12/2020 - 01/2011
3	Ovarian Neoplasms (Ovarian Cancer) 01/2013 - 12/2011
3	Vaccinia 09/2008 - 10/2005
2	Prostatic Neoplasms (Prostate Cancer) 11/2019 - 01/2018
2	Atherosclerosis 11/2013 - 03/2012
2	Lung Neoplasms (Lung Cancer) 01/2011 - 10/2007
2	Herpes Simplex 05/2003 - 04/2002
1	Primary Myelofibrosis (Myelosclerosis) 02/2022
1	Metaplasia 12/2020
1	Stomach Neoplasms (Stomach Cancer) 12/2020
1	Gastritis 12/2020
1	Neuroblastoma 01/2020
1	Autoimmune Diseases (Autoimmune Disease) 01/2019

Drug/Important Bio-Agent (IBA)

14	Pharmaceutical PreparationsIBA 12/2020 - 01/2003
11	Proteins (Proteins, Gene)FDA Link 01/2022 - 12/2002
10	Chemokine CXCL12IBA 01/2018 - 10/2009
8	Phosphotransferases (Kinase)IBA 02/2022 - 01/2019
8	LuciferasesIBA 01/2022 - 12/2002
8	Biomarkers (Surrogate Marker)IBA 12/2021 - 07/2008
8	Chemokine ReceptorsIBA 01/2020 - 12/2004
7	ChemokinesIBA 01/2019 - 10/2007
7	CXCR4 Receptors (CXCR4 Receptor)IBA 01/2018 - 06/2009
7	Firefly LuciferasesIBA 12/2011 - 12/2002
6	LigandsIBA 02/2021 - 12/2004
6	CollagenIBA 01/2021 - 07/2014
6	Biological ProductsIBA 01/2020 - 11/2016
5	HydrogelsIBA 01/2022 - 02/2015
4	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 02/2022 - 03/2019
4	Protein Isoforms (Isoforms)IBA 01/2017 - 05/2014
3	EnzymesIBA 01/2022 - 06/2008
3	beta-Arrestin 1IBA 01/2022 - 03/2012
3	RNA (Ribonucleic Acid)IBA 01/2021 - 05/2014
3	plerixafor FDA Link 01/2013 - 12/2004
3	Tumor Viral Antigens (Large T Antigen)IBA 10/2008 - 05/2002
2	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 01/2022 - 12/2019
2	Estrogen ReceptorsIBA 01/2022 - 01/2020
2	G-Protein-Coupled Receptors (Receptors, G Protein Coupled)IBA 02/2021 - 01/2019
2	AlginatesIBA 01/2021 - 01/2018
2	Mitogen-Activated Protein KinasesIBA 12/2020 - 01/2020
2	Protein Kinases (Protein Kinase)IBA 01/2020 - 01/2010
2	PhytochemicalsIBA 01/2020 - 07/2015
2	Extracellular Matrix ProteinsIBA 01/2020 - 11/2016
2	NAD (NADH)IBA 01/2020 - 01/2019
2	Caspase 3 (Caspase-3)IBA 06/2018 - 12/2017
2	Monoclonal AntibodiesIBA 10/2016 - 01/2016
2	Proteasome Endopeptidase Complex (Proteasome)IBA 01/2015 - 07/2003
2	Antiviral Agents (Antivirals)IBA 06/2008 - 10/2003
2	InterferonsIBA 10/2005 - 10/2003
2	Thymidine KinaseIBA 05/2003 - 04/2002
1	FibrinIBA 01/2022
1	Estrogens (Estrogen)FDA Link 01/2022
1	EmulsionsIBA 01/2022
1	Contrast MediaIBA 01/2022
1	IronIBA 01/2022
1	Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)IBA 01/2022
1	Proto-Oncogene Proteins c-akt (Protein Kinase B)IBA 01/2022
1	Pyruvate KinaseIBA 01/2022
1	ErbB Receptors (EGF Receptor)IBA 02/2021
1	tyrosine receptor (receptor, tyrosine)IBA 02/2021
1	Fatty Acids (Saturated Fatty Acids)IBA 01/2021
1	Fibronectins (Fibronectin)IBA 01/2021
1	Matrix Metalloproteinase 9 (Gelatinase B)IBA 01/2021
1	spasmolytic polypeptideIBA 12/2020
1	InflammasomesIBA 12/2020
1	QuercetinIBA 01/2020
1	fisetinIBA 01/2020
1	MK 2206IBA 01/2020
1	Leflunomide (Arava)FDA LinkGeneric 01/2020
1	Thioredoxin-Disulfide ReductaseIBA 01/2020
1	Tamoxifen FDA LinkGeneric 01/2020
1	Bovine Serum AlbuminIBA 12/2019
1	Lactic Acid (Lactate)FDA LinkGeneric 11/2019
1	MTOR InhibitorsIBA 03/2019
1	MitogensIBA 03/2019
1	GelsIBA 01/2019
1	NanogelsIBA 01/2019
1	Plasminogen Activator Inhibitor 1IBA 01/2019
1	Fibrillar CollagensIBA 01/2019
1	Collagen Type I (Type I Collagen)IBA 01/2019
1	nanolucIBA 01/2018
1	Biocompatible Materials (Biomaterials)IBA 01/2018
1	Tyrosine Kinase InhibitorsIBA 01/2018
1	Technetium Tc 99m MedronateIBA 01/2018
1	cabozantinibIBA 01/2018
1	Immune Checkpoint InhibitorsIBA 11/2017

Therapy/Procedure

35	Therapeutics 02/2022 - 12/2002
7	Drug Therapy (Chemotherapy) 12/2020 - 07/2015
2	Precision Medicine 01/2020 - 01/2018
2	Lab-On-A-Chip Devices 12/2019 - 06/2009
1	Castration 01/2018